WikiDoc Resources for Plateletpheresis
Evidence Based Medicine
Guidelines / Policies / Govt
Patient Resources / Community
Healthcare Provider Resources
Continuing Medical Education (CME)
Experimental / Informatics
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us  to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Plateletpheresis (also called thrombapheresis or thrombocytapheresis) is the process of collecting platelets, the components of blood that are involved in hemostasis (blood clotting). It can be a life-saving procedure in preventing or treating serious complications from bleeding and hemorrhage in patients who have disorders manifesting as thrombocytopenia (low platelet count) or platelet dysfunction. This process may also be used therapeutically to treat disorders resulting in extraordinarily high platelet counts such as Essential Thrombocytosis.
Indications for transfusion
Platelet transfusions are traditionally given to those undergoing chemotherapy for leukemia, those with aplastic anemia, AIDS, hypersplenism, ITP, sepsis, DIC, or surgeries such as cardiopulmonary bypass. Platelet transfusions should be avoided in those with TTP-HUS because it can worsen neurologic symptoms and acute renal failure, presumably due to creation of new thrombi as the platelets are consumed. It should also be avoided in those with heparin-induced thrombocytopenia (HIT).
Thrombocytopenia due to underproduction. Patients in this category falls under those undergoing chemotherapy, those with myelophthisic marrow, AIDS, or with aplastic anemia. If indicated, transfusions (one plateletpheresis concentrate) should be given until recovery of platelet function, generally approximately twice weekly. Surgical bleeding due solely to thrombocytopenia occurs when platelets < 50,000/uL while spontaneous bleeding occurs when platelets < 10,000/uL. Thrombocytopenic patients can develop "dry" bleeding, that is, petechiae and ecchymoses only. They will not suffer fatal hemorrhagic events unless they first have extensive mucosal bleeding, or "wet" bleeding. Therefore, in those with no bleeding or only "dry" bleeding, the threshold for transfusion should be between 5,000 to 10,000/uL. A more conservative threshold of 20,000/uL should be used in those with a fever or other risk factors for bleeding. Those with active bleeding or prior to surgery should have a threshold of 50,000/uL. An unconfirmed, but helpful, way to determine whether a patient is recovering from chemotherapy-induced thrombocytopenia is to measure "reticulated" platelets, or young RNA-containing platelets, which signifies that the patient is starting to make new platelets.
Immune thrombocytopenia. Patients in this category include those with ITP or drug-induced thrombocytopenia. Platelet transfusions are generally not recommended for this group of patients because the underlying cause involves antibodies that destroy platelets, therefore any newly transfused platelets will also be destroyed. More studies need to be done.
Altered platelet functions. Disorders of platelet function can be congenital or acquired. Most of these disorders are mild and may respond to therapy with desmopressin (dDAVP). Transfusion is not necessarily required. However, with some more severe disorders such as Glanzmann thrombasthenia, transfusions with large amount of platelets may be needed. The number of transfusions may be reduced if these patients are given recombinant human factor VIIa since the underlying cause are antibodies to platelet glycoproteins IIb/IIIa.
Cardiopulmonary bypass surgery. This surgery can result in destruction of a large proportion of the patient's platelets and may render the remaining viable platelets to be dysfunctional. The indications for transfusion in such patients is controversial. General guidelines recommends not transfusing patients prophylactically but only when they are bleeding excessively, while also giving desmopressin.
Drug-induced platelet dysfunction. The most common of these is aspirin, and its similar drug class, the NSAIDs. Other antiplatelet drugs are commonly prescribed for patients with acute coronary syndromes such as clopidogrel and ticlopidine. When surgery is undertaken following the administration of these drugs, bleeding can be serious. Transfusion under these circumstances is not clear-cut and one has to use clinical judgment in these cases.
Expected platelet increase after transfusion
Platelet count increase as well as platelet survival after transfusion is related to the dose of platelets infused and to the patient's body surface area (BSA). Usually these values are less than what would be expected.
- Corrected platelet count increment (CCI) = platelet increment at one hr x BSA (m2) / # platelets infused x 1011
- Expected platelet increase (per μL) = platelets infused x CCI / BSA (m2)
The theoretical value of the CCI is 20,000/μL but clinically, the value is more close to 10,000/μL. If the CCI is less than 5,000/μL, patients are said to have "refractoriness" to platelet transfusion.
The separation of individual blood components is done with a specialized centrifuge (see apheresis). The earliest manual forms of plateletpheresis are done by the separation of platelets from multiple bags of whole blood collected from donors or blood sellers. Since each blood bag (usually 250 ml or 500 ml) contains a relatively small number of platelets, it can take as many as a dozen blood bags (usually from 5 to 10 bags, depending on the size of the blood bags and each donor's platelet count) to accumulate a single unit of platelets (enough for one patient). This greatly increases the risks of the transfusion. Each unit of platelets separated from donated whole blood is called a "platelet concentrate".
Modern automatic plateletpheresis allows the blood donor to give a portion of his platelets, while keeping his or her red blood cells and at least a portion of blood plasma. Therefore, no more than three units of platelets are generally harvested in any one sitting from a donor. Most donors will donate a "single" or "double" unit, "triples" are rare.
Because platelets have a life-span of just 5 days, more platelet donors are always needed. Some centers are experimenting with 7 day platelets, but this requires additional testing and the lack of any preservative solutions means that the product is far more effective when fresh.
Even though red blood cells can also be collected in the process, most blood donation organizations do not do so because it takes much longer for the human body to replenish their loss. If the donor donates both red blood cells and platelets, it takes months, rather than days or weeks, before they are allowed to donate again (the guidelines regarding blood donation intervals are country-specific).
In most cases, blood plasma is returned to the donor as well. However, in locations that have plasma processing facilities, a part of the donor's plasma can also be collected in a separate blood bag (see plasmapheresis).
Due to their higher relative density, white blood cells are collected as an unwanted component with the platelets. Since it takes up to 3 liters of whole blood (the amount of a dozen of blood bags) to generate a dose of platelets, white blood cells from one or several donors will also be collected along with the platelets. A 70 kg (154 lb) man has only about 6 liters of blood. If all of the incidentally collected white blood cells are transfused with the platelets, substantial rejection problems can occur. Therefore, it is standard practice to filter out white blood cells before transfusion by the process of leukoreduction.
Early platelet transfusions used a filter to remove white blood cells at the time of transfusion. It takes a trained person about 10 minutes to assemble the equipment, and this is not the safest or most efficient means of filtration because living white blood cells can release cytokines during storage and dead white blood cells can break up into smaller fragments that can still stimulate a dangerous response from the immune system. In addition, simple filtration can lead to increased risks of infection and loss of valuable platelets. Newer, more advanced plateletpheresis machines can filter white blood cells during separation.
For example, with marginally acceptable whole blood (white blood cells: < 10,000/mm³; platelets: > 150,000/mm³), a dose (3×1011) of platelets comes with about 2×1010 white blood cells. This can seriously damage the patient's health. A dose of single-donor platelets prepared using latest filters can contain as little as 5×104 white blood cells.
There are two types of manual platelet apheresis. Platelet-rich plasma (PRP) is widely used in North America and Buffy coat (BC) is more widely used in Europe.
Platelets are the clotting factor of your blood, and when donated, frequently go to cancer patients, because due to chemotherapy many cancer patients are unable to generate enough platelets of their own.
The basic principles of automatic platelet apheresis are the same as in the manual procedure, but the whole procedure is performed by a computer-controlled machine. Since the donor's blood is processed in a sterile single-use centrifuge, the unwanted components can be returned to the donor safely. This allows the apheresis machine to repeat the draw-centrifuge-return cycle to obtain more platelets. The bulk of the machine and the length of the donation process means most platelet donations are done in blood centers instead of mobile blood drives.
A platelet donor must usually weigh at least 50 kg (110 lb) and have a platelet count of at least 150×105/mm³. Each country has its own rules to protect the safety of both donor and recipient. One unit has about 3×1011 platelets. Therefore, it takes 2 liters of blood having a platelet count of 150×105/mm³ to produce one unit of platelets. Some regular donors have higher platelet counts (over 300×105/mm³); for those donors, it only takes about one liter of their blood to produce a unit. Since the machine used to perform the procedure uses suction to pull blood out of your body, some people that can give whole blood may have veins too small to use for platelet donation. Your blood center can evaluate you prior to donation.
Blood accounts for about 8% of body weight, giving a 50 kg donor about four liters of blood. No more than 50% of platelets are ever extracted in one sitting, and they can be replenished by the body in about three days.
Most newer apheresis machines can separate a dose of platelets in about 60 to 120 minutes depending on the donor's health condition.
After a mini-physical, the donor is taken into the donation room and sits in a chair next to the machine. The tech cleans one arm with iodine, or other disinfectant, and inserts the needle. The process takes about one to two hours while blood is pulled into the machine, spun around, and replaced along with an anticoagulant, usually Sodium Citrate. The donor may have the option of donating a unit of plasma with the platelets, if he chooses. The donor's blood is pulled into the machine and returned to the donor usually about 6-8 times, accounting for the length of the donation.
Occasional side effects of the donation of platelets include tingling, chills, slight nausea, bruising, fatigue, and dizziness. Frequently while donating your lips may begin to tingle; the techs usually keep a supply of calcium antacid tablets close by because the anticoagulant works by binding to the calcium in your blood. Since calcium is used in the operation of the nervous system, nerve-ending-dense areas (like your lips) are suscepible to the tingling. Usually chewing a handful of antacid tablets will raise calcium levels and relieve the tingling. Bruising may also occur. Fatigue and dizziness are generally not as common after donating platelets as it is after donating blood because you get your red blood cells back.
Aside from the procedure, donating platelets is different from donating blood in a few ways.
First, you cannot take aspirin for anywhere from 36 to 72 hours prior to your donation. (Guidelines vary by blood center.) The reason for this is that aspirin is a potent drug that prevents platelets from working. Some blood centers also prohibit the taking of ANY NSAID (non-steroidal-anti-inflammatory-drug) for 36-hours prior. Different centers have different policies, so contact the center before donating. Other medications such as clopidogrel (Plavix) may also affect platelet function and may affect donor eligibility.
Second, you are generally allowed to donate platelets anywhere from every 3-28 days. This is a stark contrast to whole-blood donation, which has an eight-week (or longer) waiting period between donations. Along those lines, since platelet donation does temporarily remove whole-blood from your body, you may have to wait eight weeks after a whole blood donation to donate platelets. In the US, a donor is only allowed to donate 24 times each year and may not lose more red blood cells or plasma in a year than they would from the maximum allowable number of Whole Blood donations. Very few donors are affected by these limits.
Third, you may be required to have some additional tests done before becoming a donor for the first time. These tests are used to establish your platelet count, and also possibly to determine your compatibility with particular recipients through an HLA (Human Leukocyte Antigen) test. The tests usually involve nothing more involved than the drawing of several tubes of blood.
The Haemonetics machine draws a large amount of blood in each cycle.
Usually 5-7 cycles per donation (approx. 10 min per cycle). You can donate up to two platelet units during one donation (this is done with donors with a high count), and a unit of plasma can also be donated, at the center's discretion.
The Trima Automated Blood Collection System can collect two doses within two hours. This unit also draws more suction than the Haemonetics and lacks an automated arm cuff. This means it requires a pretty fair-sized vein to support unless a portable blood pressure cuff is available.
The Trima collection system has incorporated a leukocyte reduction "cone" as part of the disposable kit. Use of this device routinely produce platelet concentrates with White Blood Cell counts of less than 1×106 per product.
However, the Trima draws and returns blood in very small amounts compared to the Haemonetics, resulting in more than 100 cycles/unit (draw 40 sec, return 15 sec). This generally results in a lower pressure drop during the cycle since less blood is out of your body at any one time.
"Trima" can also perform the collection of platelets, plasma and red blood cells simultaneously.
COBE (Gambro) Spectra
This older unit is still in use in some blood centers. While it can perform a single-needle donation, the most common method with this machine is to draw with one needle, and return with the other, continuously drawing the blood through a centrifuge (instead of using cycles). For obvious reasons, the single needle Trima and Haemonetics machines are more popular, while the COBE Spectra is being phased out.
Repeated platelet donations at short intervals will cause the venipuncture site to scar. While cosmetically it is virtually invisible, the scarring also occurs on the vein itself, making it harder to insert a needle on future occasions. Anecdotal reports have said that rubbing Vitamin E oil (or the insides of a Vitamin E capsule) on the venipuncture site may reduce scarring.
It may be necessary to warn anybody outside of the blood center that needs to draw blood from that site that your vein may be somewhat tougher than normal. Failure to do so may result in the tech thinking they have missed the vein, not realizing that the vein simply takes a little more pressure to stick.
- Stroncek DF, Rebulla P (2007). "Platelet transfusions". Lancet. 370 (9585): 427–38. PMID 17679020. doi:10.1016/S0140-6736(07)61198-2.
- http://www.centralbloodbank.org (Pittsburgh and western Pennsylvania)
- http://www.lifesource.org (Chicago, Illinois)
- http://www.fbsblood.org/ (Tampa Bay Area)
- http://www.lifesouth.org/donorservices/donor_services2.htm (donation centers located in Florida, Georgia, and Alabama)
- http://www.redcross.org/services/biomed/0,1082,0_554_,00.html (donation centers all over the US, including Alaska and Hawaii, and Puerto Rico)
- http://www.cbccts.org/donating/automated.htm (Indiana and Ohio)
- http://www.lifeshare.org/donation/apheresis.html (Louisiana, Texas)
- http://www.lifeblood.org/donating/donating_platelets.htm (Tennessee, Arkansas, Mississippi)
- http://www.kcblood.org/donating/donating_platelets.htm (Missouri, Kansas)
- http://psbc.org/programs/platelets.htm (Washington)
- http://www.nybloodcenter.org/index.jsp (New York)
- http://www.unitedbloodservices.org/pheresis.html (California, Nevada, Utah, New Mexico, Arizona, Colorado, Texas, Oklahoma, Wyoming, Minnesota, North and South Dakota, Montana, Louisiana, Mississippi.... etc)
- http://www.rexbloodservices.com/centers/blood/index_blood.htm (Raleigh, North Carolina)
- http://www.giveblood.org (Gulf Coast Regional Blood Center)
- http://www.bloodcenter.org (MVRBC - Mississippi Valley Reginal Blood Center)
- http://www.utahblood.org (ARUP Blood Services at the University of Utah)
- http://www.vablood.org (Virginia)
- http://www.blood.co.uk (National Blood Service throughout England and Wales)
Cost Effectiveness of Plateletpheresis
| group5 = Clinical Trials Involving Plateletpheresis | list5 = Ongoing Trials on Plateletpheresis at Clinical Trials.gov • Trial results on Plateletpheresis • Clinical Trials on Plateletpheresis at Google
| group6 = Guidelines / Policies / Government Resources (FDA/CDC) Regarding Plateletpheresis | list6 = US National Guidelines Clearinghouse on Plateletpheresis • NICE Guidance on Plateletpheresis • NHS PRODIGY Guidance • FDA on Plateletpheresis • CDC on Plateletpheresis
| group7 = Textbook Information on Plateletpheresis | list7 = Books and Textbook Information on Plateletpheresis
| group8 = Pharmacology Resources on Plateletpheresis | list8 = AND (Dose)}} Dosing of Plateletpheresis • AND (drug interactions)}} Drug interactions with Plateletpheresis • AND (side effects)}} Side effects of Plateletpheresis • AND (Allergy)}} Allergic reactions to Plateletpheresis • AND (overdose)}} Overdose information on Plateletpheresis • AND (carcinogenicity)}} Carcinogenicity information on Plateletpheresis • AND (pregnancy)}} Plateletpheresis in pregnancy • AND (pharmacokinetics)}} Pharmacokinetics of Plateletpheresis •
| group9 = Genetics, Pharmacogenomics, and Proteinomics of Plateletpheresis | list9 = AND (pharmacogenomics)}} Genetics of Plateletpheresis • AND (pharmacogenomics)}} Pharmacogenomics of Plateletpheresis • AND (proteomics)}} Proteomics of Plateletpheresis
| group11 = Commentary on Plateletpheresis | list11 = Blogs on Plateletpheresis
| group12 = Patient Resources on Plateletpheresis | list12 = Patient resources on Plateletpheresis • Discussion groups on Plateletpheresis • Patient Handouts on Plateletpheresis • Directions to Hospitals Treating Plateletpheresis • Risk calculators and risk factors for Plateletpheresis
| group13 = Healthcare Provider Resources on Plateletpheresis | list13 = Symptoms of Plateletpheresis • Causes & Risk Factors for Plateletpheresis • Diagnostic studies for Plateletpheresis • Treatment of Plateletpheresis
| group14 = Continuing Medical Education (CME) Programs on Plateletpheresis | list14 = CME Programs on Plateletpheresis
| group17 = Informatics Resources on Plateletpheresis | list17 = List of terms related to Plateletpheresis